Home/Pipeline/TD-B01

TD-B01

Rheumatoid Arthritis

Pre-clinicalActive

Key Facts

Indication

Rheumatoid Arthritis

Phase

Pre-clinical

Status

Active

Company

Tridem Bioscience

About Tridem Bioscience

Tridem Bioscience is a private, preclinical-stage biotech focused on autoimmune and inflammatory diseases through a vaccine-based platform. The company is developing a lead candidate, TD-B01, for rheumatoid arthritis and other indications, aiming to induce antigen-specific immune tolerance. While still in early research and development, Tridem's approach targets a significant unmet medical need in large chronic disease markets. Its success hinges on validating its platform and advancing its pipeline through clinical trials.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active